Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co Buyback Yield % Chart
SHSE:600993 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayinglong Pharmaceutical Group Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Mayinglong Pharmaceutical Group Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a Buyback Yield % of 0.00 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Mayinglong Pharmaceutical Group Co's Buyback Yield % too high?
Mayinglong Pharmaceutical Group Co's current Buyback Yield % is 0.00. Based on the distribution chart, Mayinglong Pharmaceutical Group Co ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #999999 out of 291 companies for Buyback Yield %. This places Mayinglong Pharmaceutical Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. Mayinglong Pharmaceutical Group Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.58, compared to a current price of ¥23.90 — trading 19.2% below its estimated fair value. The current Buyback Yield % is 0.00. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current Buyback Yield % is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥23.90 is trading 19.2% below its estimated GF Value™ of ¥29.58.
GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600993:
Buyback Yield %: 0.00
GF Value™: ¥29.58 vs. price of ¥23.90 (19.2% below fair value)
No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayinglong Pharmaceutical Group Co Business Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
88GF Score
Get the complete analysis for SHSE:600993
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600993 has been successfully added to your 
